William Ki Chul Cho net worth and biography

William Cho Biography and Net Worth

Billy Cho has been our Chief Financial Officer since March 2018. Prior to joining Zai Lab, Mr. Cho was the Managing Director and Head of Asia Healthcare Investment Banking at Citigroup. Based in Hong Kong since 2011, Mr. Cho was responsible for healthcare client coverage at Citigroup across the Asia Pacific region and led many important biopharma transactions in China including Zai Lab's US IPO. Prior to this, he was based in New York in healthcare M&A investment banking and also spent time in corporate development for a pharmaceutical services company. Mr. Cho started his career at Ernst & Young performing financial audits of US-based healthcare companies.

Mr. Cho earned his M.B.A. from the Wharton School of the University of Pennsylvania and M.A. in Accounting from University of Virginia.

What is William Ki Chul Cho's net worth?: The estimated net worth of William Ki Chul Cho is at least $731,135.52 as of June 1st, 2021. Mr. Cho owns 51,416 shares of Zai Lab stock worth more than $731,136 as of April 18th. This net worth estimate does not reflect any other assets that Mr. Cho may own. Learn More about William Ki Chul Cho's net worth.
How do I contact William Ki Chul Cho?: The corporate mailing address for Mr. Cho and other Zai Lab executives is 4560 JINKE ROAD BLDG. 1 FOURTH FLOOR PUDONG, SHANGHAI F4, 201210. Zai Lab can also be reached via phone at 862161632588 and via email at [email protected]. Learn More on William Ki Chul Cho's contact information.
Has William Ki Chul Cho been buying or selling shares of Zai Lab?: William Ki Chul Cho has not been actively trading shares of Zai Lab during the last ninety days. Most recently, William Ki Chul Cho sold 8,584 shares of the business's stock in a transaction on Tuesday, June 1st. The shares were sold at an average price of $180.12, for a transaction totalling $1,546,150.08. Following the completion of the sale, the chief financial officer now directly owns 51,416 shares of the company's stock, valued at $9,261,049.92. Learn More on William Ki Chul Cho's trading history.
Who are Zai Lab's active insiders?: Zai Lab's insider roster includes Kai-Xian Chen (Director), Yajing Chen (CFO), William Cho (CFO), John Diekman (Director), Ying Du (CEO), Frazor Edmondson, III (Insider), Tao Fu (COO), William Lis (Director), Harald Reinhart (Insider), Joshua Smiley (Insider), and Peter Wirth (Director). Learn More on Zai Lab's active insiders.
Are insiders buying or selling shares of Zai Lab?: During the last twelve months, Zai Lab insiders bought shares 2 times. They purchased a total of 9,000 shares worth more than $254,250.00. During the last twelve months, insiders at the sold shares 9 times. They sold a total of 40,476 shares worth more than $940,803.05. The most recent insider tranaction occured on April, 4th when insider Joshua L Smiley sold 1,988 shares worth more than $31,151.96. Insiders at Zai Lab own 5.2% of the company. Learn More about insider trades at Zai Lab.
Information on this page was last updated on 4/4/2024.

William Ki Chul Cho Insider Trading History at Zai Lab

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/1/2021	Sell	8,584	$180.12	$1,546,150.08	51,416

William Ki Chul Cho Buying and Selling Activity at Zai Lab

Zai Lab Company Overview

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China.

Today's Range

Now: $14.22

$13.48

$14.23

50 Day Range

MA: $18.02

$13.72

$22.49

2 Week Range

Now: $14.22

$13.48

$39.50

Volume

694,734 shs

Average Volume

641,824 shs

Market Capitalization

$1.41 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.1

Biden’s $374B Giveaway Into This Sector

From DTI | Ad

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story